Drug Discovery Targeting Drug-Resistant Bacteria

Erscheinungsjahr 2020
ISBN: 978-0-12-818480-6
Verlag: ACADEMIC PRESS

Buch, Englisch, 432 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 720 g

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.

Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.

Zielgruppe

Research scientists and industry professionals in pharmaceutical science, biomedicine, microbiology, and biotechnology who are working on technological advancement in designing targeted therapies and drug delivery systems

Autoren/Hrsg.

Kesharwani, Prashant

Chopra, Sidharth

Dasgupta, Arunava

Fachgebiete

• Wirtschaftswissenschaften Wirtschaftssektoren & Branchen Fertigungsindustrie Pharmaindustrie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie

Inhaltsverzeichnis

1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria

Über Autor(innen)

Dasgupta, Arunava
Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.

Kesharwani, Prashant
Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. He has over 12 years of teaching and research experience, specializing in translational nanomedicine, polymeric biomaterials, targeted drug delivery, and nanoengineered drug delivery systems. He has authored more than 400 peer-reviewed publications in reputed international journals and edited over 30 international books. His research has received widespread recognition, with an h-index exceeding 100. He has secured several competitive research grants from national funding agencies and received prestigious honors, including the USERN Laureate Award and the SERB–Ramanujan Fellowship. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and translational pharmaceutical research. He actively contributes to academic mentoring, scientific research, and scholarly publishing.

Chopra, Sidharth
Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens.